REGENXBIO Inc. (NASDAQ:RGNX) Director Kenneth T. Mills Sells 12,221 Shares

REGENXBIO Inc. (NASDAQ:RGNX) Director Kenneth T. Mills sold 12,221 shares of the business’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $13.78, for a total transaction of $168,405.38. Following the completion of the sale, the director now owns 408,035 shares in the company, valued at $5,622,722.30. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

REGENXBIO Price Performance

Shares of REGENXBIO stock traded down $0.06 on Friday, reaching $14.33. 318,287 shares of the company were exchanged, compared to its average volume of 638,509. REGENXBIO Inc. has a 1-year low of $10.49 and a 1-year high of $28.80. The company has a market cap of $705.90 million, a P/E ratio of -2.44 and a beta of 1.26. The stock’s 50 day moving average price is $13.07 and its 200-day moving average price is $16.04.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.10). REGENXBIO had a negative return on equity of 70.72% and a negative net margin of 299.96%. The company had revenue of $15.60 million for the quarter, compared to analyst estimates of $23.52 million. During the same period in the prior year, the firm posted ($1.53) earnings per share. The business’s quarterly revenue was down 18.3% compared to the same quarter last year. On average, research analysts predict that REGENXBIO Inc. will post -4.37 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $38.00 price objective on shares of REGENXBIO in a report on Thursday, June 20th. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research note on Tuesday, June 18th. Stifel Nicolaus reiterated a “buy” rating and set a $40.00 price target on shares of REGENXBIO in a research note on Friday, April 12th. Finally, The Goldman Sachs Group initiated coverage on shares of REGENXBIO in a research note on Friday, June 7th. They set a “buy” rating and a $38.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $38.58.

Institutional Investors Weigh In On REGENXBIO

Several large investors have recently modified their holdings of RGNX. Redmile Group LLC raised its stake in shares of REGENXBIO by 21.0% during the first quarter. Redmile Group LLC now owns 4,551,556 shares of the biotechnology company’s stock worth $95,901,000 after purchasing an additional 790,866 shares during the last quarter. Assenagon Asset Management S.A. raised its position in REGENXBIO by 258.7% in the second quarter. Assenagon Asset Management S.A. now owns 816,384 shares of the biotechnology company’s stock worth $9,552,000 after acquiring an additional 588,773 shares in the last quarter. Vanguard Group Inc. raised its position in REGENXBIO by 9.8% in the first quarter. Vanguard Group Inc. now owns 4,876,881 shares of the biotechnology company’s stock worth $102,756,000 after acquiring an additional 436,043 shares in the last quarter. Perceptive Advisors LLC purchased a new position in REGENXBIO in the fourth quarter worth $6,146,000. Finally, Artal Group S.A. purchased a new position in REGENXBIO in the first quarter worth $5,268,000. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.